Congratulations to the winner of the first annual Tufts-CEVR Cost-Effectiveness Analysis Paper of the Year award for 2018!
Laiteerapong, N., Cooper, J.M., Skandari, M.R., Clarke, P.M., Winn, A.N., Naylor, R.N., & Huang, E.S. (2018). Individualized Glycemic Control for U.S. Adults with Type 2 Diabetes: A Cost-Effectiveness Analysis. Annals of Internal Medicine, 168(3), 170-178. doi: 10.7326/M17-0537
First Author: Neda Laiteerapong, Assistant Professor, Director of Primary Care Behavioral Health Integration, University of Chicago.
Dr. Laiteerapong’s paper was selected based on its exemplary methodological quality and its potential impact on decision-making and improvement of diabetic care.
Runners-up:
- Pearson-Stuttard, J., Kypridemos, C., Collins, B., Mozaffarian, D., Huang, Y., Bandosz, P., … Micha, R. (2018). Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis. PLoS Medicine, 15(4), e1002551. doi: 10.1371/journal.pmed.1002551
- Pandya, A., Doran, T., Zhu, J., Walker, S., Arntson, E., & Ryan, A.M. (2018). Modelling the cost-effectiveness of pay-for-performance in primary care in the UK. BMC Medicine, 16(1), 135. https://doi.org/10.1186/s12916
- Faria, R., Soares, M.O., Spackman, E., Ahmed, H.U., Brown, L.C., Kaplan, R., … Sculpher, M.J. (2018). Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). European Association of Urology, 73(1), 23-30. doi: 10.1016/j.eururo.2017.08.018
- Barocas, J.A., Tasillo, A, Eftekhari, Y.G., Wang, J., Vellozzi, C., Hariri, S., … Linas, B.P. (2018). Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. Clinical Infectious Diseases, 67(4), 549-556. doi: 10.1093/cid/ciy098
Thank you to everyone who submitted or nominated a paper this year; we received 25 high-quality submissions. Each submission was reviewed by an internal team, and the top five finalists were selected based on:
- methodological quality of the analysis
- timeliness and importance of the disease topic
- potential influence on policy or clinical decision-making
The Cost-Effectiveness Analysis (CEA) Registry Advisory Board selected the final winner. The Tufts Medical Center CEA Registry Advisory Board is a small group of senior leadership selected to represent a variety of stakeholder groups including industry, payer, academia, and government; current members include:
- Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York
- Dan Greenberg, PhD, Professor and Chairman, Department of Health Systems Management, School of Public Health, Faculty of Health Sciences, The Guildford Glazer Faculty of Business and Management, Ben-Gurion University of the Negev
- Kakoli Roy, PhD, Chief Economist, Office of the Associate Director for Policy, Centers for Disease Control and Prevention
- Chris Pashos, PhD, Vice President, Global Evidence Strategy, AbbVie
We will announce our call for 2019 submissions in the fall of this year.
